CORDIART® clinical results on validated cardiovascular biomarkers in healthy overweight individuals have been published in high impact scientific journal. The American Journal of Clinical Nutrition has published the results of the latest clinical study on CORDIART®. CORDIART®, a whole fruit extract from sweet orange, was evaluated in a double-blind clinical study in healthy overweight individuals and showed promising results in preventing endothelial dysfunction.
Maastricht, Netherlands, January 4, 2017
The American Journal of Clinical Nutrition, a scientific journal with the highest impact factor in nutrition science, has published the results of the latest clinical study on CORDIART® . CORDIART® , a whole fruit extract from sweet orange, was evaluated in a double-blind clinical study in healthy overweight individuals and showed promising results in preventing endothelial dysfunction. CORDIART® has been specifically developed to contain a high concentration of the most active isomer hesperidin 2S. The article concludes that “the results reflect the potential preventive therapeutic properties of hesperidin 2S.”
Endothelial dysfunction is a common problem in overweight people and hallmarks are arterial stiffness, high blood pressure, arterial chronic inflammation and plaques formation.
In a randomized, double-blind, placebo-controlled study the effects of 6-weeks daily intake of 500mg CORDIART® on endothelial function were evaluated. CORDIART® showed to reduce circulating adhesion molecules sVCAM-1 and sICAM-1 and to lower both systolic and diastolic blood pressure. Moreover CORDIART® resulted in significant improvement of flow mediated dilatation in a subgroup constituted of subject with borderline chronic endothelial impairment.
The findings from the study show promising results with CORDIART® for preserving endothelial function, thus supporting a healthy blood flow and cardiovascular health.
The results of the clinical study have recently been presented by BioActor’s Head Clinical Research with a plenary talk at the Food Bioactives & Health Conference 2016 in September in Norwich (UK).
CORDIART® can already be found on the market in several products in the USA and Europe. It can be applied in various finished dosage forms, including effervescent tablets, capsules, RTD sachets and beverages.
Feel free to contact us via firstname.lastname@example.org for more information on the possibilities CORDIART® has to offer.
Further information can be found on: www.cordiart.com.